Stevens Capital Management LP purchased a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 67,388 shares of the biopharmaceutical company’s stock, valued at approximately $8,199,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Morgan Stanley raised its holdings in Alexion Pharmaceuticals by 112.0% during the 1st quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock worth $70,983,000 after buying an additional 309,299 shares during the period. Commerzbank Aktiengesellschaft FI raised its holdings in Alexion Pharmaceuticals by 151.5% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after buying an additional 79,943 shares during the period. Baird Financial Group Inc. raised its holdings in Alexion Pharmaceuticals by 219.0% during the 1st quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $1,771,000 after buying an additional 10,028 shares during the period. LMR Partners LLP acquired a new stake in Alexion Pharmaceuticals during the 1st quarter worth about $927,000. Finally, Fox Run Management L.L.C. acquired a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $426,000. 94.26% of the stock is owned by institutional investors.
In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock valued at $2,416,869 over the last 90 days. 4.35% of the stock is currently owned by insiders.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 1.44% during midday trading on Friday, reaching $146.69. The company’s stock had a trading volume of 3,713,613 shares. The firm has a market cap of $32.74 billion, a price-to-earnings ratio of 63.61 and a beta of 1.40. The company has a 50-day moving average price of $138.83 and a 200-day moving average price of $124.75. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same period last year, the firm posted $1.13 EPS. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. Equities analysts expect that Alexion Pharmaceuticals, Inc. will post $5.62 earnings per share for the current year.
Several analysts have issued reports on ALXN shares. J P Morgan Chase & Co downgraded Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Tuesday, May 23rd. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, May 23rd. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, May 23rd. Barclays PLC restated an “overweight” rating and set a $155.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Finally, Stifel Nicolaus restated a “buy” rating and set a $157.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Five investment analysts have rated the stock with a hold rating, twenty have given a buy rating and three have issued a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $157.13.
TRADEMARK VIOLATION WARNING: This report was reported by Equities Focus and is the property of of Equities Focus. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.equitiesfocus.com/2017/09/17/stevens-capital-management-lp-takes-8-20-million-position-in-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.